UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisd ...

Corporate Presentation March 2022 Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such state ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2021 Earnings Conference Call March 17, 2022 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer William Forbes - Chief Development Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Nathan Weinstein - Aegis Capital Operator Good afternoon, and welcome to the Trevi Therapeutics Q4 and Year End 2021 Earnings Conference Call. At this time, all participants will be in listen-only mode. [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 45-0834299 | | --- | --- | | ( Sta ...

Corporate Presentation March 2022 Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such state ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Jennifer Good - President and CEO Bill Forbes - Chief Development Officer Lisa Delfini - CFO Conference Call Participants Nick Rubino - Stifel Rohit Bhasin - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2021 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions] Please note this event ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other ju ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Bill Forbes - Chief Development Officer Conference Call Participants Serge Belanger - Needham & Company Operator Good afternoon and welcome to the Trevi Therapeutics Q2 2021 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportuni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 TREVI THERAPEUTICS, INC. For the transition period from to Commission File Number: 001-38886 (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisdi ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Gary Nachman – BMO Capital Markets Serge Belanger – Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2021 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator ...